Monitoring disease in lymphoma and CLL patients using molecular techniques

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 1, 2002, Pages 179-195

  Gribben, John G ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Chromosomal translocation; Chronic lymphocytic leukaemia; Immunoglobulin gene rearrangement; Non Hodgkin's lymphoma; Polymerase chain reaction; Residual disease

Indexed keywords

IMMUNOGLOBULIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ARTICLE; ASSAY; B CELL LYMPHOMA; CANCER DIAGNOSIS; CELL COUNT; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CLONING; CONTROLLED STUDY; DISEASE COURSE; GENE REARRANGEMENT; HUMAN; IMMUNOGLOBULIN GENE; LEUKEMIA CELL; LYMPHOMA; LYMPHOMA CELL; MINIMAL RESIDUAL DISEASE; MOLECULAR BIOLOGY; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT INDICATION; TUMOR CELL; GENE TRANSLOCATION; GENETICS; NONHODGKIN LYMPHOMA; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE RECEPTOR GENE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW CELL; CELL INFILTRATION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 18; CHROMOSOME TRANSLOCATION 2; CHROMOSOME TRANSLOCATION 5; CHROMOSOME TRANSLOCATION 8; GENETIC VARIABILITY; MONITORING;

GENE REARRANGEMENT; GENES, IMMUNOGLOBULIN; GENES, T-CELL RECEPTOR; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA, NON-HODGKIN; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; TRANSLOCATION, GENETIC;

EID: 0036009613     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0191     Document Type: Article

References (85)

1. Immunoglobulin gene rearrangement as a diagnostic criterion of B cell lymphoma
2. Immunoglobulin genes: Rearrangement and translocation in human lymphoid malignancy
3. Genes of the T-cell antigen receptor in normal and malignant T cells
4. Detection of B cell lymphoma in peripheral blood by DNA hybridization
5. Enzymatic amplification of betaglobin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia
6. Distinctive chromosomal abnormalities in histological subtypes of non-Hodgkin's lymphoma
7. The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas
8. The bcl-2 gene is rearranged in many diffuse B-cell lymphomas
9. H on chromosome 14 and near a transcriptional unit on 18
10. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18
11. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining
12. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation
13. Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas
14. Structure of the human immunoglobulin μ locus: Characterization of embryonic and rearranged J and D genes
15. Detection of minimal residual disease carrying the t(14;18) by DNA sequence amplification
16. Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease
17. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment
18. Translocation t(14;18) in benig B lymphocytes
19. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals
20. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation
21. Clustering of breakpoints on chromosome II in human B-cell neoplasms with the t(11;14) chromosome translocation
22. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster
23. Rearrangement of CCNDI (BCLI/PRADI) 3′ untranslated region in mantle cell lymphomas and t(11q13)-associated leukemias
24. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas
25. Failure of immunologic purging in mantle cell lymphoma assessed by PCR detection of minimal residual disease
26. The t(8;14) chromosomal translocation occurring in B-cell malignancies results from mistakes in V-D-J joining
27. Localization of breakpoints by polymerase chain reaction in Burkitt's lymphoma with 8;14 translocations
28. Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb
29. Molecular characterization of the t(2;5) (p23;q35) translocation in anaplastic large cell lymphoma (Ki-l) and Hodgkin's disease
30. Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B cells
31. A κ-immunoglobulin gene is formed by site-specific recombination without further somatic mutation
32. An immunoglobulin heavy chain variable region gene is generated from three segments of DNA
33. Identification and nucleotide sequence of a diversity DNA segment (D) of immunoglobulin heavy chain genes
34. Somatic generation of antibody diversity
35. An improved method for detection of B-lymphoid clonality by polymerase chain reaction
36. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: A technique for sequential quantitation of residual disease
37. Third complementarity determining region (CDR III) sequence analysis in childhood B-lineage acute lymphoblastic leukaemia: Implications for the design of oligonucleotide probes for use in monitoring minimal residual disease
38. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation
39. Eradication of PCR Detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation
40. Eradication of polymerase chain reaction immunoglobulin gene rearrangement in non-Hodgkin's lymphoma as associated with decreased relapse after autologous bone marrow transplantation
41. Rearranged immunoglobulin light chain genes as minimal residual disease markers in intermediate- and high-grade malignant B cell non-Hodgkin's lymphoma
42. Multiplex PCR reaction for the detection and identification of immunoglobulin kappa deleting element rearrangements in B-lineage leukaemias
43. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors
44. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia
45. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia
46. Blastic variant of mantle cell lymphoma shows a heterogenous pattern of somatic mutations of the rearranged immunoglobulin heavy chain variable genes
47. Clonal evolution of a follicular lymphoma: Evidence for antigen selection
48. Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma
49. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells
50. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells
51. Ig rearrangements in isolated Reed-Sternberg cells: Conclusions from four different studies
52. Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: Evidence from the Ig heavy chain gene
53. Myeloma VL and VH gene sequences reveal a complementary imprint of antigen selection in tumor cells
54. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma
55. Molecular monitoring of low grade non-Hodgkin's lymphoma by gene amplification
56. Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early stage and advanced stage follicular lymphoma
57. Sensitive and reproducible detection of occult disease in patients with follicular lymphoma by PCR amplification of t(14;18) both pre- and post-treatment
58. Clinical significance of translocation t(14;18) positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission
59. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
60. The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma
61. The clinical significance of molecular response in indolent follicular lymphomas
62. Detection of small numbers of monoclonal B lymphocytes in the blood of patients with B cell lymphoma
63. Detection of bcl-2/JH rearrangement in follicular and diffuse lymphoma: Concordant results of peripheral blood and bone marrow analysis at diagnosis
64. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow
65. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
66. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
67. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high dose chemotherapy and peripheral blood progenitor cell autografting
68. Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: A critical reappraisal of molecular strategies
69. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma
70. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up
71. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
72. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
73. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of δ and γ T-cell receptor genes
74. Quantitative PCR techniques and applications
75. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts
76. Detection of specific polymerase chain reaction product by utilizing the 5′ → 3′ exonuclease activity of Thermus aquaticus DNA polymerase
77. Allelic discrimination by nick-translation PCR with fluorogenic probes
78. A rapid and quantitative assay to estimate gene transfer into retrovirally transduced hematopoietic stem/progenitor cells using a 96-well format PCR and fluorescent detection system universal for MMLV-based proviruses
79. Novel 5′ exonuclease-based real-time PCR assay for the detection of t(14;18)(q32;q21) in patients with follicular lymphoma
80. Quantitative detection of t(14;18)-positive cells by real-time quantitative PCR using fluorogenic probes
81. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukemia patients using real-time quantitative RT-PCR
82. Detection of minimal residual disease in patients with AMLl/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay
83. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes
84. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia
85. IgM monoclonal antibody JD118 recognizes an inducible antigen target for human-complement-mediated cytotoxicity against neoplastic B cells